
FDA Issues Most Serious Risk Level for Cookie Recall
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The Food and Drug Administration (FDA) has issued its highest risk warning after a California-based company recalled cookies due to potential undeclared allergens.
Jalux Americas, Inc, doing business as J.sweets, issued a voluntary recall on July 14 for multiple units of its L'espoir cookies because of undeclared milk, and its Drycapot cookies because of undeclared tree nuts (almond and macadamia nuts).
The FDA has now classified the recall as Class I, its most serious category. On its website, the FDA states a Class I is "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death."
Newsweek approached Jalux Americas, Inc. via an email outside of office hours for an updated statement.
Why it Matters
In its original announcement posted on the FDA's website, Jalux Americas, Inc. said that "people who have an allergy or severe sensitivity to milk and/or tree nuts (almond and macadamia nuts) run the risk of serious or life-threatening allergic reaction if they consume these products."
A stock image of a split cookie. The FDA has issued a Class I classification, its highest risk category, after California-based Jalux Americas, Inc. initiated a recall of cookie products
A stock image of a split cookie. The FDA has issued a Class I classification, its highest risk category, after California-based Jalux Americas, Inc. initiated a recall of cookie products
Gavin Woodruff/iStock / Getty Images Plus
Food allergies are a significant health concern in the United States, with milk and tree nuts among the nine major food allergens identified under federal law. The others are milk, eggs, fish, crustacean shellfish, peanuts, wheat, soybeans, and sesame.
Allergies are an immune system's response to a substance. Allergic reactions can vary in severity from coughing and a runny nose to a life-threatening reaction known as anaphylaxis.
According to the CDC's National Center for Health Statistics, almost 6 percent of U.S. adults and children have a food allergy.
What To Know
The recall, announced on July 14, 2025, affects:
L'espoir cookies (32 units, UPC: 4 942737 200147, code: L4FN, best before 09/26/2025) for undeclared milk
Drycapot cookies (28 units, UPC: 4 942737 210191, code: D4FN, best before 09/26/2025) for undeclared tree nuts (almond and macadamia nut)
The products were distributed in California, Illinois, and Washington and sold exclusively at J.sweets retail locations in Torrance, CA, and San Jose, CA, Arlington Heights, IL; and Lynnwood, WA. The L'espoir cookies were on sale from May 26 to June 30, 2025, and the Drycapot cookies from May 31 to June 30, 2025. No online sales occurred.
Product images released by Jalux Americas, Inc.via the FDA alongside a product recall of L'espoir Brand L'espoir cookies and L'espoir Brand Drycapot cookies
Product images released by Jalux Americas, Inc.via the FDA alongside a product recall of L'espoir Brand L'espoir cookies and L'espoir Brand Drycapot cookies
Jalux Americas, Inc./FDA
Jalux Americas, Inc. said the recall was "initiated after it was discovered during an inventory audit that L'espoir product containing Milk and the Drycapot product containing Tree Nuts were inadvertently distributed in packaging that did not reveal the presence of those allergens."
As of July 17, no illnesses have been reported.
In an earlier statement provided to Newsweek, Jalux Americas, Inc. said: "Those who have allergies to the ingredients that were inadvertently undeclared on the labels should refrain from consuming the products and return them to the store where they purchased for a full refund."
The company added: "As part of our preventive measures, our supplier partner has added a step at their manufacturing facility to verify that the product matches the label after it is applied, and to record this verification in the production log. Our supplier partner will also reinforce allergy and manufacturing procedure training at the facility." The company further stated, "At the retail store level, we will strengthen our checks during stocking to ensure there are no discrepancies between products and labels, not just for the manufacturer of the recalled products but across all items. We would like to clarify that we have thus far not received any inquiries from consumers regarding this matter."
The FDA says on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food."
What Happens Next
Consumers who have purchased L'espoir L4FN and Drycapot D4FN products with the best before date of 09/26/2025 are urged to return it to the place of purchase for a full refund.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
34 minutes ago
- Associated Press
Integrated Dermatology Welcomes Mohs Surgeon Dr. Partik Singh to Dermatology Associates of Westlake Village
BOCA RATON, Fla.--(BUSINESS WIRE)--Aug 13, 2025-- Integrated Dermatology, the country's largest independent dermatology provider, proudly announces that Partik Singh, M.D., has joined the clinical team at Dermatology Associates of Westlake Village. Fellowship-trained Mohs and reconstructive surgeon Dr. Singh, who specializes in skin cancer treatment, dermatologic surgery, cosmetic dermatology, and general medical dermatology, is now serving patients in Westlake Village and surrounding communities across Southern California. At Dermatology Associates of Westlake Village, Dr. Singh works alongside lead partner physician Simone Montgomery, M.D., M.P.H., and three additional dermatologists to provide comprehensive medical, surgical and cosmetic dermatology services. He specializes in skin cancer surgery, specifically Mohs micrographic surgery; reconstructive surgery for skin cancer; cosmetic dermatology; and general medical dermatology. His goal is to empower patients with high-quality treatment plans, education and compassionate support to ensure they feel confident and well informed. Dr. Singh earned a bachelor's degree in biochemistry from Case Western Reserve University before completing his M.D. and M.B.A. at Northwestern University's Feinberg School of Medicine and Kellogg School of Management. He served as chief resident during his dermatology residency at the University of Rochester Medical Center and completed a fellowship in micrographic surgery and dermatologic oncology at the University of California, San Francisco. 'Dr. Singh's expertise in skin cancer surgery and his compassionate approach to patient care make him a tremendous asset to our team,' said Dr. Montgomery. 'We're excited to welcome him and confident that his skills will greatly enhance the care we provide to our patients and the community.' Dermatology Associates of Westlake Village offers a full range of dermatology services to help patients maintain healthy skin. The practice provides general dermatology, dermatologic surgery, cosmetic treatments, microneedling and Ultherapy. To learn more about Singh and the practice, visit About Integrated Dermatology Headquartered in Boca Raton, Fla., Integrated Dermatology is one of the largest providers of dermatology services, empowering doctors nationwide through practice acquisitions, physician partnerships and new practice formations. Founded in 2004, the company operates in 28 states and enables its dermatologists to maintain their medical autonomy. With a doctor-driven philosophy and focus on high-quality patient care, Integrated Dermatology provides unparalleled back-office support, including accounting, payroll, human resources and much more. The company also offers career opportunities for dermatologists seeking to join an established practice. For additional information, visit View source version on CONTACT: MEDIA CONTACT: Jason Queen Chief of Staff [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA INDUSTRY KEYWORD: GENERAL HEALTH HEALTH OTHER HEALTH SOURCE: Integrated Dermatology Copyright Business Wire 2025. PUB: 08/13/2025 06:07 AM/DISC: 08/13/2025 06:07 AM


Time Business News
37 minutes ago
- Time Business News
Rybelsus Medical Weight Loss Program
Losing weight can be one of the most challenging goals a person faces. Despite efforts with diet and exercise, many find it difficult to shed excess pounds or keep the weight off long term. At Family Medical Centers, we offer a medical weight loss program that includes innovative treatments like Rybelsus, designed to help you succeed in your weight management journey. For many, weight loss isn't just about appearance—it's about improving overall health and reducing risks related to obesity, such as diabetes, heart disease, and joint problems. Sometimes, diet and exercise alone don't provide enough support. Medical weight loss programs step in to fill this gap, combining expert guidance with proven medications. Rybelsus, a medication containing Semaglutide, is part of this modern approach. It supports the body's natural systems that regulate hunger and metabolism, making weight loss more achievable and sustainable. Rybelsus is an FDA-approved oral medication originally developed to treat type 2 diabetes. It works by mimicking the hormone GLP-1, which helps regulate blood sugar and appetite. By activating GLP-1 receptors, Rybelsus helps reduce hunger, slows digestion, and improves insulin sensitivity. This unique combination means people using Rybelsus often feel fuller longer and eat less, which supports steady weight loss when paired with lifestyle changes. The active ingredient, Semaglutide, acts on GLP-1 receptors found in the brain and digestive system. This action helps: Reduce appetite by affecting hunger signals Slow gastric emptying, which prolongs feelings of fullness Enhance insulin response, improving blood sugar control These benefits work together to make it easier for patients to maintain healthy eating habits and lose weight effectively. At Family Medical Centers, weight loss treatment is never one-size-fits-all. Our team designs personalized plans tailored to your health status and goals. If Rybelsus is suitable for you, it will be integrated alongside nutrition counseling, physical activity guidance, and ongoing medical supervision. The program includes: A thorough initial health evaluation Customized diet and exercise plans Medication management and education Regular progress reviews and support This comprehensive method helps patients achieve lasting success. Clinical research shows that Rybelsus users can experience meaningful weight loss, especially when combined with healthy habits. Key benefits include: Noticeable weight reduction, especially in individuals with a higher BMI Improved blood sugar regulation and metabolic health Better appetite control leading to reduced calorie intake Assistance in maintaining weight loss long-term Together, these advantages make Rybelsus a valuable tool in the fight against obesity. Starting Rybelsus involves working closely with your healthcare provider to find the right dose and monitor your response. Many patients experience reduced hunger and slower digestion early on, which naturally helps with portion control. Side effects can include mild nausea or digestive discomfort, but these typically improve as your body adjusts. Regular follow-ups ensure your plan remains safe and effective. We know that weight loss is deeply personal and can be influenced by many factors including genetics, lifestyle, and medical history. Our care team is dedicated to providing ongoing encouragement and adapting your plan as needed. By combining Rybelsus with individualized coaching and medical oversight, Family Medical Centers helps patients overcome barriers and build healthier, sustainable habits. Can I take Rybelsus if I don't have diabetes? Yes, Rybelsus is now commonly prescribed for weight management even in individuals without diabetes. How quickly will Rybelsus help me lose weight? Results vary, but many patients notice appetite changes and weight loss within weeks. Are there risks or side effects? Side effects are usually mild and may include nausea or stomach upset. Your healthcare provider will monitor you closely. Will I need to stay on Rybelsus forever? This depends on your individual health and weight goals; your provider will help determine the best course. Is lifestyle change necessary when taking Rybelsus? Yes, combining Rybelsus with healthy eating and exercise yields the best results. Weight loss is rarely simple, but with the right support, it's achievable. Family Medical Centers offers a caring, personalized program that uses modern tools like Rybelsus to assist your journey toward a healthier life. TIME BUSINESS NEWS

Associated Press
2 hours ago
- Associated Press
FDA Report: Synthetic 7-OH Products Pose Severe Opioid Risks
Agency finds 7-OH products lack safety data, carry high abuse potential, and risk respiratory failure The Stop Gas Station Heroin coalition today applauded the U.S. Food and Drug Administration's release of a new report, " 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat.' Its findings confirm what public health experts have long warned: Concentrated 7-OH opioid products are not natural kratom, but highly addictive synthetic opioids that put American consumers at serious risk. The FDA's Center for Drug Evaluation and Research (CDER) found that: '7-OH isn't a wellness product; it's a synthetic opioid,' said Dr. Nicole Avena, research neuroscientist and expert in addiction. 'The FDA's findings reinforce what we've seen clinically — these products carry real risks of dependency, overdose, and long-term harm. Selling them as dietary supplements is misleading and dangerous.' The FDA report also notes that results across multiple independent studies align: Preclinical addiction models show the high-risk profile of concentrated 7-OH, making it clear that these substances should not be marketed directly to consumers. Despite being packaged as 'natural' remedies, concentrated 7-OH products are chemically manufactured drugs that are illegally sold without FDA approval. Some are branded as pain relievers or treatments for opioid withdrawal despite lacking any clinical proof of safety or effectiveness. 'Objective science has spoken,' added Avena. 'Concentrated 7-OH opioid products are illegal, unapproved new drugs. Until companies produce peer-reviewed clinical research and secure FDA new drug approval, these products must be kept off the market to protect American families.' About Stop Gas Station Heroin Stop Gas Station Heroin is a national coalition that aims to educate consumers about harmful synthetic drugs and advocate for smart regulation that distinguishes between legitimate, natural botanicals and dangerous, synthetic drugs, combined with enforcement of current federal laws around unapproved drugs. To learn more, navigate to Media Contact Media Contact [email protected] ### SOURCE: Stop Gas Station Heroin Copyright 2025 EZ Newswire